FDA Approves Selumetinib for Children With NF1 and Inoperable Tumors

FDA Expands Selumetinib to Children With NF1-Associated Plexiform Neurofibromas

Selumetinib gains expanded FDA approval for younger pediatric patients with neurofibromatosis type 1 plexiform neurofibromas, enhancing treatment options and addressing significant disease-related challenges.

FDA Approves Selumetinib for Children With NF1 and Inoperable Tumors

FDA expands selumetinib approval to younger children with NF1-related tumors.

FDA Approves Selumetinib in Patients 1 Year and Older for NF1 with PN

The FDA approves selumetinib for young patients with neurofibromatosis type 1, offering hope for effective treatment of inoperable tumors.

FDA Approves Selumetinib in Pediatric Neurofibromatosis Type 1

The FDA approved selumetinib as treatment for pediatric neurofibromatosis type 1, expanding options for young patients with inoperable plexiform neurofibromas.